Arcutis Biotherapeutics/ARQT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Ticker

ARQT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Todd Watanabe

Employees

296

Headquarters

Westlake village, United States

ARQT Metrics

BasicAdvanced
$968M
Market cap
-
P/E ratio
-$2.91
EPS
1.17
Beta
-
Dividend rate
$968M
1.16838
$13.17
$1.76
3.3M
9.894
9.614
90.158
90.158
-6.52%
-50.68%
-119.24%
-56.21%
9.096
4.293
4.425
1,545.18%
48.77%

What the Analysts think about ARQT

Analyst Ratings

Majority rating from 7 analysts.
Buy

ARQT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-71.31% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$50M
266.67%
Net income
-$35M
-46.68%
Profit margin
-71.31%
-85.46%

ARQT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 56.16%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.16
-$0.73
-$0.72
-$0.32
-
Expected
-$1.25
-$0.86
-$0.78
-$0.73
-$0.57
Surprise
-7.21%
-14.87%
-7.10%
-56.16%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Arcutis Biotherapeutics stock?

Arcutis Biotherapeutics (ARQT) has a market cap of $968M as of June 17, 2024.

What is the P/E ratio for Arcutis Biotherapeutics stock?

The price to earnings (P/E) ratio for Arcutis Biotherapeutics (ARQT) stock is 0 as of June 17, 2024.

Does Arcutis Biotherapeutics stock pay dividends?

No, Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Arcutis Biotherapeutics dividend payment date?

Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders.

What is the beta indicator for Arcutis Biotherapeutics?

Arcutis Biotherapeutics (ARQT) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Arcutis Biotherapeutics stock price target?

The target price for Arcutis Biotherapeutics (ARQT) stock is $19, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Arcutis Biotherapeutics stock

Buy or sell Arcutis Biotherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing